Point72 Asset Management’s Century Therapeutics IPSC Stock Holding History

Point72 Asset Management’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.5M	Buy	5,964,678 +3,047	+0.1%	+$6.41K	0.02%	1039
2025 Q4	$5.93M	Buy	+5,961,631	New	+$3.64M	0.01%	1714
2023 Q1	–	Sell	-82,100	Closed	-$421K	–	2390
2022 Q4	$421K	Sell	82,100 -83,100	-50%	-$784K	﹤0.01%	1165
2022 Q3	$1.63M	Sell	165,200 -315,800	-66%	-$3.33M	0.01%	970
2022 Q2	$4.04M	Buy	481,000 +13,610	+3%	+$133K	0.02%	763
2022 Q1	$5.88M	Buy	467,390 +56,590	+14%	+$750K	0.02%	657
2021 Q4	$6.51M	Buy	+410,800	New	+$7.72M	0.03%	618

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management's IPSC Position: Q1 2026 in Review

Point72 Asset Management increased its Century Therapeutics (IPSC) stake by 0.05% in Q1 2026, buying an estimated $6.41K and bringing the position to 5,964,678 shares worth $13.5M. The position accounts for 0.02% of the portfolio, ranked #1039.

Point72 Asset Management first reported a position in IPSC in Q4 2021 and has held it in 7 quarters since. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

Point72 Asset Management held 5,964,678 shares of Century Therapeutics worth $13.5M as of Q1 2026.
Point72 Asset Management bought 3,047 Century Therapeutics shares in Q1 2026, an estimated $6.41K.
Century Therapeutics made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #1039 holding.
Point72 Asset Management first reported a position in Century Therapeutics in Q4 2021 and has held it in 7 quarters since.
72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.